Accordingly, FASN and SCD1 inhibitors have been subjected to clinical trials with a view to ascertaining their potential utility in the treatment of patients with obesity or MASLD [67,68]. This evidence concerns the gene FASN and obesity due to melanocortin 4 receptor deficiency.